Amgen’s NDA for heart failure drug ivabradine gets FDA priority review status
The NDA is based on global clinical trial results from the large, multi-center, randomized, double-blind, placebo-controlled, outcomes Phase III Systolic Heart failure treatment with the If inhibitor ivabradine
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.